Evaluation of weight change and hypoglycaemia as mediators in the association between insulin use and death
- PMID: 31373104
- PMCID: PMC7055153
- DOI: 10.1111/dom.13846
Evaluation of weight change and hypoglycaemia as mediators in the association between insulin use and death
Abstract
Aim: To evaluate whether weight change or hypoglycaemia mediates the association between insulin use and death.
Materials and methods: In a retrospective cohort of veterans who filled a new prescription for metformin and added insulin or sulphonylurea (2001-2012), we assessed change in body mass index (BMI) and hypoglycaemia during the first 12 months of treatment intensification. Cox proportional hazards models compared the risk of death between treatment groups. Using the difference method, we estimated the indirect effect and proportion mediated through each mediator. A sensitivity analysis assessed mediators in the first 6 months of intensified therapy.
Results: Among 28 892 patients surviving 12 months, deaths per 1000 person-years were 15.4 for insulin users and 12.9 for sulphonylurea users (HR 1.20, 95% CI 0.87, 1.64). Change in BMI and hypoglycaemia mediated 13% (-98, 98) and -1% (-37, 71) of this association, respectively. Among 30 214 patients surviving 6 months, deaths per 1000 person-years were 34.8 for insulin users and 21.3 for sulphonylurea users (HR 1.66, 95% CI 1.28, 2.15). Change in BMI and hypoglycaemia mediated 9% (1, 23) and 0% (-9, 4) of this association, respectively.
Conclusions: We observed an increased risk of death among metformin users intensifying treatment with insulin versus sulphonylurea and surviving 6 months of intensified therapy, but not among those surviving 12 months. This association was mediated in part by weight change.
Keywords: hypoglycaemia; insulin therapy; sulphonylureas; type 2 diabetes; weight control.
Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
Conflict of interest statement
Figures
Similar articles
-
Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.J Gen Intern Med. 2016 Jun;31(6):638-46. doi: 10.1007/s11606-016-3633-2. J Gen Intern Med. 2016. PMID: 26921160 Free PMC article.
-
Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.BMJ. 2016 Jul 13;354:i3625. doi: 10.1136/bmj.i3625. BMJ. 2016. PMID: 27413017 Free PMC article.
-
Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.PLoS Med. 2019 Dec 26;16(12):e1002999. doi: 10.1371/journal.pmed.1002999. eCollection 2019 Dec. PLoS Med. 2019. PMID: 31877127 Free PMC article.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Hypoglycaemic valleys: an under-recognised problem in type 2 diabetes?Int J Clin Pract Suppl. 2002 Jul;(129):12-9. Int J Clin Pract Suppl. 2002. PMID: 12166599 Review.
References
-
- ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–328. - PubMed
-
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853. - PubMed
-
- ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008;358(24):2560–2572. - PubMed
-
- Duckworth WC, Abraira C, Moritz TE, et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complicat. 2011;25(6):355–361. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical